Evidence map›Paper›PMID 34561286›Full record

ArticleThe European respiratory journal2022

Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis.

Jesse D Kirkpatrick, Ava P Soleimany, Jaideep S Dudani, Heng-Jia Liu, Hilaire C Lam, Carmen Priolo, Elizabeth P Henske, Sangeeta N Bhatia

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jesse D KirkpatrickKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Ava P SoleimanyKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Jaideep S DudaniKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Heng-Jia LiuPulmonary and Critical Care Medicine, Dept of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Hilaire C LamPulmonary and Critical Care Medicine, Dept of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Carmen PrioloPulmonary and Critical Care Medicine, Dept of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Elizabeth P HenskePulmonary and Critical Care Medicine, Dept of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Sangeeta N BhatiaKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA sbhatia@mit.edu.
Brigham and Women's Hospital · USHarvard–MIT Division of Health Sciences and Technology · USMassachusetts Institute of Technology · USMicrosoft Research New England (United States)

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond · 1985 to 2026
$93.9M
TOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YAFFE, MICHAEL B · 1985 to 2020
$25.6M
MOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA014051NIEHS NIH HHS P30 ES002109NIGMS NIH HHS T32 GM008313
6 · The paper itself

Abstract

backgroundBiomarkers of disease progression and treatment response are urgently needed for patients with lymphangioleiomyomatosis (LAM). Activity-based nanosensors, an emerging biosensor class, detect dysregulated proteases

methods

resultsMultiple activity-based nanosensors (PP03 (cleaved by metallo, aspartic and cysteine proteases), p

conclusionsActivity-based nanosensors enable noninvasive, real-time monitoring of disease burden and treatment response in a pre-clinical model of LAM.

Indexed as

Cysteine ProteasesLymphangioleiomyomatosisAnimalsFemaleHumansMiceMice, NudePeptide HydrolasesSirolimusCysteine ProteasesPeptide HydrolasesSirolimus

Identifiers

PMID34561286
PMCPMC9030069
OpenAlexW3199045483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.